The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C value - an Evaluation of Rosuvastatin therapY compared with atorvastatin

Página do item simplificado
dc.contributor.authorFonseca, Francisco Antonio Helfenstein [UNIFESP]
dc.contributor.authorRuiz, A.
dc.contributor.authorCardona-Munoz, E. G.
dc.contributor.authorSilva, J. M.
dc.contributor.authorFuenmayor, N.
dc.contributor.authorMarotti, M.
dc.contributor.authorDISCOVERY PENTA investigators
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionPontificia Univ Javeriana
dc.contributor.institutionUniv Guadalajara
dc.contributor.institutionUniv Coimbra
dc.contributor.institutionHosp Miguel Perez Carreno
dc.contributor.institutionAstraZeneca
dc.date.accessioned2016-01-24T12:38:00Z
dc.date.available2016-01-24T12:38:00Z
dc.date.issued2005-08-01
dc.description.abstractBackground. International guidelines emphasize the need to achieve recommended low-density lipoprotein cholesterol (LDL-C) levels in order to reduce morbidity and mortality associated with coronary heart disease (CHD). However, many patients with hypercholesterolemia fail to achieve LDL-C goals on treatment.Objective: the primary objective was to compare the efficacy of rosuvastatin and atorvastatin for enabling patients to achieve National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goals. Secondary objectives were European LDL-C goal achievement, changes in the lipid profile, and safety. Research design and methods: This 12-week, multicenter, multinational, randomized, open-label trial compared the efficacy and safety of rosuvastatin 10 mg with atorvastatin 10 mg in statin-naive and switched patients with primary hypercholesterolemia from Brazil, Colombia, Mexico, Portugal, and Venezuela.Results: A total of 1124 patients with similar baseline characteristics were randomized to the two treatment groups. After 12 weeks of treatment, a significantly greater percentage of patients receiving rosuvastatin 10mg compared with atorvastatin 10 mg achieved NCEP ATP III LDL-C goals (71.2% vs 61.4%, p < 0.001), 1998 European LDL-C goals (73.5% vs 59.2%, p < 0.001) and 2003 European LDL-C goals (58.9% vs 44.6%, p < 0.001). Rosuvastatin treatment was associated with significant reductions in LDL-C and total cholesterol (TC) and, in statin-naive patients, a significant increase in high-density lipoprotein cholesterol (HDL-C) compared with atorvastatin treatment. Both treatments were well tolerated with a similar incidence of adverse events. Clinically significant elevations in creatinine, creatine kinase or hepatic transaminases were low and similar between treatment groups.Conclusions: Rosuvastatin 10 mg is significantly more effective at achieving NCEP ATP III and European LDL-C goals, lowering LDL-C and TC in both naive and switched patients and increasing HDL-C in naive patients than atorvastatin 10 mg, with a similar safety and tolerability profile. This study also provides evidence regarding the comparative effects of rosuvastatin versus atorvastatin in Latin American and Portuguese populations.en
dc.description.affiliationUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationPontificia Univ Javeriana, Med Interna & Epidemiol Clin, Bogota, Colombia
dc.description.affiliationUniv Guadalajara, Guadalajara 44430, Jalisco, Mexico
dc.description.affiliationUniv Coimbra, Serv Med 2, P-3000 Coimbra, Portugal
dc.description.affiliationHosp Miguel Perez Carreno, Serv Nefrol Dialisis & Transplante, Caracas, Venezuela
dc.description.affiliationAstraZeneca, Macclesfield, Cheshire, England
dc.description.affiliationUnifespUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent1307-1315
dc.identifierhttp://dx.doi.org/10.1185/030079905X56529
dc.identifier.citationCurrent Medical Research and Opinion. Newbury: Librapharm, v. 21, n. 8, p. 1307-1315, 2005.
dc.identifier.doi10.1185/030079905X56529
dc.identifier.issn0300-7995
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/28421
dc.identifier.wosWOS:000231469300021
dc.language.isoeng
dc.publisherLibrapharm
dc.relation.ispartofCurrent Medical Research and Opinion
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectatorvastatinen
dc.subjectcardiovascular diseaseen
dc.subjectcoronary heart diseaseen
dc.subjecthigh-density lipoprotein cholesterolen
dc.subjectlow-density lipoprotein cholesterolen
dc.subjectrosuvastatinen
dc.subjecttriglyceridesen
dc.titleThe DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C value - an Evaluation of Rosuvastatin therapY compared with atorvastatinen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos